Max Chat
Clinuvel Pharmaceuticals Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
8/10
|
14.26 | 54.24 | -73.7% | 36.53 | -60.96% |
| P/S |
|
5.76 | 4.62 | 24.74% |
|
|
| P/BV |
|
2.5 | 4.2 | -40.35% |
|
|
| P/FCF |
|
0 | 16.2 | -100% |
|
|
| Ev/Ebitda |
|
5.78 | 14.71 | -60.7% |
|
|
| Ev/S |
|
3.69 | 4.05 | -8.97% |
|
|
| Ev/FCF |
|
15.45 | 20.97 | -26.32% |
|
|
| E/P |
|
0 | 1.63 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
10/10
|
63.82 | 25.2 | 153.26% | 58.23 | +9.61% |
| ROE |
|
22.79 | 12.46 | 82.83% |
|
|
| ROA |
|
19.75 | 6.23 | 216.99% |
|
|
| ROIC |
|
19.97 | 15.34 | 30.19% |
|
|
| ROS |
|
40.41 | 12.71 | 217.96% |
|
|
| ROCE |
|
27.16 | 14.68 | 84.99% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0.0156 | 6.22 | -99.75% | 0.0277 | -43.61% |
| Nеt Debt/Ebitda |
|
-3.25 | -3.47 | -6.39% |
|
|
| Debt/Ratio |
|
0.0038 | 0.2246 | -98.31% |
|
|
| Debt/Equity |
|
0.1385 | 1 | -86.17% |
|
|
| Debt/Net Income |
|
0.0247 | 18.36 | -99.87% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0.78/10
|
0.3148 | 2.28 | -86.2% | 0.1942 | +62.12% |
| Number of years of dividend growth |
|
3 | 1.59 | 88.5% | ||
| DSI |
|
1 | 0.7935 | 26.03% |
|
|
| Average dividend growth |
|
12.93 | -303.64 | -104.26% |
|
|
| Average percentage for 5 years |
|
0.1942 | 2.59 | -92.51% |
|
|
| Average percentage for payments |
|
6.9 | 167.32 | -95.88% |
|
|
| Difference from average difference in sector |
|
-1.97 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
170.49 | -98.5 | -273.09% | ||
| Growth impulse Ebitda in 5 years |
|
313.79 | -98.62 | -418.18% | ||
| Growth impulse Net Income in 5 years |
|
114.68 | -98.32 | -216.64% | ||
| Growth impulse FCF in 5 years |
|
58.24 | -98.32 | -159.24% | ||
| Growth impulse EPS in 5 years |
|
111.63 | -82.03 | -236.08% |
IP Score
7.63/10
